Targeting Residual Inflammation in Cardiovascular Disease

Episode Summary

Executive Summary: Rosera CEO Jeff Madonna argues that residual inflammatory risk is a major unmet need in cardiovascular and neuroinflammatory disease, even when LDL is controlled. He explains how the company’s oral NLRP3 inhibitor ravonoflast is engineered for strong tissue and brain penetration, summarizes encouraging clinical data, and outlines a Phase III program in peripheral artery disease plus a next-generation brain-focused program.

Main Topics: Residual inflammatory risk as a disease driver (Priority: 5/5): Madonna frames chronic inflammation as a central accelerator of cardiovascular, metabolic, and neurologic disease that persists despite standard therapies like statins and lipid-lowering drugs. NLRP3 biology and selective anti-inflammatory targeting (Priority: 5/5): He explains NLRP3 as a key inflammasome that drives sterile inflammation from internal damage signals, and why inhibiting it may reduce chronic inflammation while preserving host defense against infection. Ravonoflast differentiation and tissue/brain penetration (Priority: 5/5): The lead asset is described as an oral, potent NLRP3 inhibitor with unusually high tissue distribution and the highest recorded human brain exposure among NLRP3 inhibitors. Clinical evidence and biomarker strategy (Priority: 4/5): The discussion reviews completed human studies, biomarker engagement with hsCRP and other markers, and the distinction between proving pathway inhibition versus demonstrating patient-relevant outcomes. Peripheral artery disease as Phase III lead indication (Priority: 5/5): PAD was chosen because of its large unmet need, high inflammatory burden, and severe functional impact, with limited disease-specific innovation since 1999. Next-generation CNS program: trabzanoflast (Priority: 4/5): Rosera is developing a separate, more brain-optimized NLRP3 inhibitor for neuroinflammatory diseases and is using cerebrospinal fluid data and imaging to guide future indications. Capital strategy and broader portfolio vision (Priority: 3/5): Madonna says Rosera is not solely a single-target company; it plans multiple NLRP3 profiles, possible combination approaches, and a mosaic of financing options ahead of registrational studies.

Key Arguments: Inflammation is an independent, clinically meaningful risk driver in cardiovascular disease, not just a byproduct of high LDL or hypertension. NLRP3 is a particularly attractive target because it mediates sterile inflammation from internal damage while leaving infection defense intact. Biomarkers such as hsCRP helped validate the inflammation hypothesis and identify patients with elevated residual inflammatory risk. Ravonoflast is differentiated by oral dosing, strong tissue penetration, and unusually high brain access, making it suitable for both vascular and neurologic tissues. Prior NLRP3 inhibitors were limited by poor bioavailability and tissue access, which likely prevented meaningful impact on diseased tissues. Phase I/II data across more than 400 exposed patients support moving ravonoflast into Phase III. PAD is an ideal Phase III setting because it is common, costly, inflammatory, and largely underserved by current standards of care. Rosera believes real clinical value must be shown through outcomes that matter to patients, such as walking ability in PAD, not biomarker changes alone. Trabzanoflast is being designed for even greater CNS specialization, with CSF sampling used to support development decisions. The company expects NLRP3 inhibitors to be used alongside statins, GLP-1s, and other therapies rather than as replacements.

Data Points: Global cardiovascular mortality: World’s leading cause of death - Used to emphasize the size of the unmet need in cardiovascular disease Human exposure to ravonoflast: More than 400 patients - Total patient exposure across completed clinical trials Completed clinical trials for ravonoflast: 4 completed trials + 1 completed but unreported study - Includes SAD/MAD, two Phase 1b studies, and RESOLV-1 RESOLV-1 sample size: 176 patients - Largest and longest Phase 2 study of ravonoflast Diabetes prevalence in RESOLV-1: 50% - Half of study participants had diabetes and half did not PAD prevalence in the U.S.: About 20 million people - Supports the rationale for choosing PAD as lead Phase III indication PAD patients with elevated residual inflammatory risk: About 85% - Company estimate of inflammatory burden in PAD Annual U.S. healthcare cost of PAD: Over $21 billion - Illustrates economic burden of peripheral artery disease Last disease-specific PAD approval: 1999 - Highlights how little innovation has occurred in PAD therapy Late-stage PAD population: About 500,000 patients - Patients with limb-threatening disease targeted by antithrombotic approaches Volume of distribution for ravonoflast: 15 liters - Compared by Madonna to a typical NLRP3 inhibitor value of around 5 liters Typical volume of distribution for most NLRP3 inhibitors: Around 5 liters - Used as a benchmark for tissue penetration Brain KPUU for ravonoflast: 1.5 - Described as the highest recorded human KPUU for an NLRP3 inhibitor Brain exposure relative to plasma: 50% higher in brain than peripheral circulation - Derived from the KPUU value of 1.5 Inflammation time horizon: Three decades - Refers to the field’s progress from hypothesis to clinical validation Company runway: Well into next year - Current cash is expected to support operations into the next year

Pivotal Quotes: "Inflammation while preserving the immune system's ability to respond to infection." — Transcript intro: Defines the intended therapeutic profile of the experimental NLRP3 inhibitor "Can I just say yes? It's all of those things, right?" — Jeff Madonna: Asked where ravonoflast may fit clinically alongside statins, GLP-1s, and biomarker-defined patient groups "We don't think this is going to be a Lord of the Rings moment where there'll be one ring to rule them all." — Jeff Madonna: Explaining that Rosera expects multiple NLRP3-targeted molecules optimized for different tissues and indications

Implications: If Phase III succeeds, NLRP3 inhibition could become a new adjunct therapy for high-risk inflammatory disease, especially PAD, and open a broader market in cardiometabolic and CNS disorders where standard risk factors are already treated.